VAI TRÒ CỦA THANG ĐIỂM SARC-F TRONG DỰ ĐOÁN NGUY CƠ TIẾN TRIỂN Ở BỆNH NHÂN COVID-19 CAO TUỔI ĐIỀU TRỊ TẠI BỆNH VIỆN DÃ CHIẾN TRUYỀN NHIỄM 5G

Abstract

Objectives: To investigate the association between the risk of myasthenia gravis and disease severity in elderly COVID-19 patients. Methods: A prospective cohort study of 182 hospitalized elderly patients (≥60 years of age) with confirmed COVID-19 pneumonia between September 6, 2021 and October 30, 2021. Epidemiological, sociodemographic, clinical and laboratory data on admission and outcome data were extracted from electronic medical records. All patients were assessed for myasthenia gravis on admission using the SARC-F score and as a result the development of worsening disease during hospital stay. We used the Cox proportional hazard model to determine the association between sarcopenia and disease progression. Results: Among 182 patients, 87 (47.8%) were at high risk for sarcopenia while 95 (52.2%) were not. We found that 42 (23.1%) patients progressed to more severe cases. COVID-19 patients at higher risk of developing sarcopenia were more likely to develop severe disease than those without (36.8% vs 10.5%, p <0.001). After adjusting for demographic and clinical, and laboratory factors, a higher risk of sarcopenia was associated with a higher risk of severe condition [hazard ratio =6.37  (95% CI: 1,61-25,18)]. Conclusion: The risk of sarcopenia in elderly patients with COVID-19 was common. People with at higher risk of sarcopenia were more likely to develop more serious conditions. A simple physician assessment of sarcopenia can provide early warning in older patients who are at high risk for more severe COVID-19 pneumonia.